STIMULUS trial demonstrates improvement in hemodynamic performance in mechanically ventilated patients
Lungpacer Medical today unveiled promising results from its Phase 1 STIMULUS clinical study that evaluates diaphragm neurostimulation to enhance hemodynamic performance in patients on invasive mechanical ventilation.
The study, presented at the 2025 Transcatheter Heart Therapies (THT) conference, highlights the AeroNova system, a next-generation neurostimulation technology developed by Lungpacer. The investigational system utilizes transvenous phrenic nerve stimulation to contract the diaphragm, improving cardiovascular function and reducing the negative effects typically seen with mechanical ventilation.
Key Study Insights:
- 19 patients enrolled, including those with acute hypoxemic respiratory failure or post-thoracic surgery respiratory failure.
- 16 patients received AeroNova stimulation, and 75% had pre-existing cardiac dysfunction.
- Results showed significant improvement in cardiac index and stroke volume, indicating better heart performance and enhanced blood flow.
- Hemodynamic stability was maintained, with a decrease in pulmonary artery pressure.
The study suggests a dose-response relationship: increasing diaphragm stimulation led to enhanced cardiac and pulmonary hemodynamics, paving the way for further exploration of this novel therapy to combat the harmful cardiovascular effects of positive pressure ventilation.
Follow MEDWIRE.AI for more insights on advancements in respiratory and cardiovascular medical technologies.
